Stocks
Atara Biotherapeutics Financial Statements (ATRA) |
||||||||||
| Atara Biotherapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 08.05.2023 | 08.08.2023 | 01.11.2023 | 28.03.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1.23 | 0.957 | 2.14 | 4.25 | 27.4 | 34.7 | |||
| Operating Income, bln rub | -75.0 | -71.4 | -69.6 | -53.3 | -26.5 | -220.8 | ||||
| EBITDA, bln rub | ? | -75.0 | -68.5 | -67.2 | -52.1 | -25.1 | -212.9 | |||
| Net profit, bln rub | ? | -74.8 | -71.1 | -69.8 | -60.5 | -31.8 | -233.1 | |||
| OCF, bln rub | ? | -38.4 | -52.8 | -51.3 | -50.4 | -29.6 | -184.2 | |||
| CAPEX, bln rub | ? | 0.399 | 0.499 | 0.281 | 0.044 | 0.127 | 0.951 | |||
| FCF, bln rub | ? | -38.8 | -53.3 | -51.6 | -50.5 | -29.7 | -185.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 76.0 | 69.5 | 69.1 | 54.4 | 51.9 | 244.8 | ||||
| Cost of production, bln rub | 0.216 | 2.90 | 2.62 | 3.16 | 1.99 | 10.7 | ||||
| R&D, bln rub | 62.2 | 56.1 | 56.9 | 44.0 | 42.1 | 199.1 | ||||
| Interest expenses, bln rub | 1.34 | 1.38 | 1.40 | 1.18 | 1.15 | 5.10 | ||||
| Assets, bln rub | 302.1 | 246.4 | 188.8 | 165.5 | 165.3 | 165.3 | ||||
| Net Assets, bln rub | ? | 65.0 | 7.45 | -50.8 | -99.2 | -98.3 | -98.3 | |||
| Debt, bln rub | 54.9 | 64.7 | 61.8 | 57.9 | 92.3 | 92.3 | ||||
| Cash, bln rub | 205.4 | 153.6 | 102.4 | 51.9 | 46.4 | 46.4 | ||||
| Net debt, bln rub | -150.5 | -88.9 | -40.6 | 6.00 | 46.0 | 46.0 | ||||
| Ordinary share price, rub | 2.90 | 1.61 | 1.48 | 0.513 | 0.694 | 1.20 | ||||
| Number of ordinary shares, mln | 104.0 | 105.1 | 106.4 | 108.1 | 140.6 | 140.6 | ||||
| Market cap, bln rub | 302 | 169 | 157 | 55 | 98 | 169 | ||||
| EV, bln rub | ? | 151 | 80 | 117 | 61 | 144 | 215 | |||
| Book value, bln rub | 65 | 7 | -51 | -99 | -98 | -98 | ||||
| EPS, rub | ? | -0.72 | -0.68 | -0.66 | -0.56 | -0.23 | -1.66 | |||
| FCF/share, rub | -0.37 | -0.51 | -0.49 | -0.47 | -0.21 | -1.32 | ||||
| BV/share, rub | 0.62 | 0.07 | -0.48 | -0.92 | -0.70 | -0.70 | ||||
| EBITDA margin, % | ? | -6 119% | -7 161% | -3 144% | -1 225% | -91.8% | -613.5% | |||
| Net margin, % | ? | -6 099% | -7 430% | -3 265% | -1 422% | -116.1% | -671.7% | |||
| FCF yield, % | ? | -75.1% | -126.6% | -127.4% | -350.2% | -189.7% | -109.7% | |||
| ROE, % | ? | -330.9% | -4 086% | 570.9% | 278.3% | 237.1% | 237.1% | |||
| ROA, % | ? | -71.2% | -123.6% | -153.7% | -166.8% | -141.0% | -141.0% | |||
| P/E | ? | -1.40 | -0.56 | -0.54 | -0.20 | -0.42 | -0.72 | |||
| P/FCF | -1.33 | -0.79 | -0.78 | -0.29 | -0.53 | -0.91 | ||||
| P/S | ? | 5.25 | 24.7 | 34.7 | 6.47 | 2.81 | 4.86 | |||
| P/BV | ? | 4.64 | 22.7 | -3.10 | -0.56 | -0.99 | -1.72 | |||
| EV/EBITDA | ? | -0.48 | -0.27 | -0.41 | -0.23 | -0.67 | -1.01 | |||
| Debt/EBITDA | 0.48 | 0.29 | 0.14 | -0.02 | -0.22 | -0.22 | ||||
| R&D/CAPEX, % | 15 578% | 11 251% | 20 245% | 99 957% | 33 159% | 20 938% | ||||
| CAPEX/Revenue, % | 32.5% | 52.1% | 13.1% | 1.03% | 0.46% | 2.74% | ||||
| Atara Biotherapeutics shareholders | ||||||||||
